Stress Urinary Incontinence
Conditions
Brief summary
There are many existing treatments of female stress urinary incontinence such as the use of adult absorbent pads and diapers, behavioral training, including bladder training, pelvic muscle exercises, biofeedback, urethral plugs, intravaginal prosthesis, electrical stimulation, periurethral injections, and reconstructive surgery. However, there is still a lack of effective minimally invasive treatment options that are independent of patient compliance. One emerging approach of minimally invasive SUI therapy is pelvic floor reinforcement using laser therapy. The primary objective of this post-marketing study is to confirm the effectiveness and safety of the FotonaSmooth® device in the treatment of stress urinary incontinence (SUI) in a large number of females using objective and subjective methods. Patients with stress incontinence will be assigned to two groups, an active group, where the Fotona Dynamis Er:YAG Laser System will be used, and a sham group where a very low laser setting will be used, and parameter presentations will be masked. Participants will be adult females, 18 years old and older with clinical and urodynamic diagnosis of Stress Urinary Incontinence,who have had no significant improvement in urinary incontinence from at least one previous conservative treatment, such as behavioral measures, pelvic floor muscle training or the use of absorbent pads
Detailed description
Prospective, randomized, 2-treatment, sham-controlled, single (patient only) blinded, study design using convenience sampling to enroll subjects as they present and are found to be eligible per the inclusion/exclusion criteria. This multicenter clinical trial utilizes a randomized assignment allocation schedule stratified by clinical site. Allocation rule pertains to the ratio of subjects in each treatment arm. Sampling rules pertain to the number of subjects in each active treatment arm. Two treatment arms enrolled on a 2:1 ratio: Active arm is the Fotona Dynamis Er:YAG Laser System and the control arm is a sham treatment with a very low laser setting and parameter presentations masked. The active arm subjects will be followed out to 12 months post-treatment. The sham arm subjects will be followed out to 6 months and then offered the active treatment.
Interventions
Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
DEVICEFotona Dynamis Er:YAG Laser System with sham handpience
Sham treatment with a sham handpiece and parameter presentations masked
Sponsors
Fotona d.o.o.
Cork University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult Female, 18 years of age or older, * Clinical and UDS diagnosis of Stress Urinary Incontinence, * No significant improvement in urinary incontinence from at least one previous conservative treatments, such as behavioral measures, pelvic floor muscle training or the use of absorbent pads
Exclusion criteria
1. Pre-existing bladder pathology including prior radiation treatment 2. Pregnancy 3. BMI\>35 4. Radical pelvic surgery or previous incontinence surgery 5. Urinary tract infection or other active infections of urinary tract or bladder 6. Endometriosis 7. Any form of pelvic organ prolapse greater than stage 2, according to POP-Q 8. Diagnosis of urge incontinence 9. Diagnosis of collagen disorders e.g. benign joint hypermobility / Elhers-Danlos / Marfans etc. 10. Incomplete bladder emptying 11. Vesicovaginal fistula 12. Fecal incontinence 13. Unwillingness or inability to complete follow-up schedule 14. Unwillingness or inability to give Informed Consent 15. Failure to comply with diary requirements during extended baseline period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy: Reduction in 1-hour pad weight between active and sham groups | 6 months post-treatment | Reduction in 1-hour pad weight at 6 months post-treatment in active group vs the sham treated group at 6 months post treatment |
| Safety: Incidence and severity of device related Adverse Events | 6 months post-treatment | Incidence and severity of device related Adverse Events (i.e., infections, edema, superficial burns, increased vaginal discharge, de novo urge incontinence). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in King's Health Questionnaire (KHQ) | from baseline to 6 and 12 months post-treatment. | Change in mean KHQ from baseline to 6 and 12 months post-treatment |
| Change in mean PISQ-12 test scores | from baseline to 6 and 12 months post-treatment. | Change in mean PISQ-12 test scores from baseline to 6 and 12 months post-treatment. |
| Durability of the effect | 12 months post-treatment | Reduction in 1hr pad test weight in the treated group at 12 month follow-up vs. pad weight in the same group at baseline |
| Change in International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF) score | from baseline to 6 and 12 months post-treatment. | Change in mean ICIQ-SF from baseline to 6 and 12 months post-treatment |
| Subjective assessment of pain | 6 months | Patient reported assessment of pain during treatment |
| Improvement | 6 and 12 months post-treatment | Change in mean Cough Stress test score at 6 and 12 months post-treatment |
Countries
Germany, Greece, Ireland, Slovenia, Switzerland, United Kingdom
Outcome results
None listed